Plasmid encoding matrix protein of vesicular stomatitis viruses as an antitumor agent inhibiting rat glioma growth in situ

Exp Oncol. 2007 Jun;29(2):85-93.

Abstract

Aim: Oncolytic effect of vesicular stomatitis virus (VSV) has been proved previously. Aim of the study is to investigate glioma inhibition effect of Matrix (M) protein of VSV in situ.

Materials and methods: A recombinant plasmid encoding VSV M protein (PM) was genetically engineered, and then transfected into cultured C6 gliomas cells in vitro. C6 transfected with Liposome-encapsulated PM (LEPM) was implanted intracranially for tumorigenicity study. In treatment experiment, rats were sequentially established intracranial gliomas with wild-typed C6 cells, and accepted LEPM injection intravenously. Possible mechanism of M protein was studied by using Hoechst staining, PI-stained flow cytometric analysis, TUNEL staining and CD31 staining.

Results: M protein can induce generous gliomas lysis in vitro. None of the rats implanted with LEPM-treated cells developed any significant tumors, whereas all rats in control group developed tumors. In treatment experiment, smaller tumor volume and prolonged survival time was found in the LEPM-treated group. Histological studies revealed that possible mechanism were apoptosis and anti-angiogenesis.

Conclusion: VSV-M protein can inhibit gliomas growth in vitro and in situ, which indicates such a potential novel biotherapeutic strategy for glioma treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Cell Growth Processes / genetics
  • Cell Line, Tumor
  • Gene Expression Regulation, Neoplastic
  • Gene Transfer Techniques
  • Genetic Engineering
  • Genetic Therapy / methods*
  • Glioma / diagnostic imaging
  • Glioma / pathology*
  • Glioma / therapy*
  • Liposomes / administration & dosage
  • Neoplasm Transplantation
  • Plasmids*
  • Radiography
  • Rats
  • Recombinant Proteins / administration & dosage
  • Transfection
  • Transplantation, Homologous
  • Viral Matrix Proteins / administration & dosage*
  • Viral Matrix Proteins / genetics

Substances

  • Antineoplastic Agents
  • Liposomes
  • M protein, Vesicular stomatitis virus
  • Recombinant Proteins
  • Viral Matrix Proteins